rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2016-339-345rsp-2230Research ArticleФОРУМ МОЛОДЫХ УЧЕНЫХYOUNG SCIENTISTS FORUMВлияние коморбидных психических расстройств на эффективность терапии у больных ревматоидным артритомIMPACT OF COMORBID MENTAL DISORDERS ON THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITISАбрамкинА. А.AbramkinA. A.

аспирант, лаборатория системных ревматических заболеваний с группой гемореологических нарушений (научный руководитель – д.м.н. Т.А. Лисицына)

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

79096237832@ya.ruФГБНУ Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201620072016543339345Copyright © Абрамкин А.А., 20162016Абрамкин А.А.Abramkin A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2230

В обзоре отечественной и зарубежной литературы приводится подробный анализ актуальных вопросов, связанных с влиянием коморбидных тревожно-депрессивных и когнитивных расстройств на эффективность противовоспалительной и болезнь-модифицирующей терапии больных ревматоидным артритом.

The review of Russian and foreign literature provides a detailed analysis of topical issues associated with the impact of comorbid anxiety and depressive disorders and cognitive impairments on the efficiency of anti-inflammatory and disease-modifying therapy in patients with rheumatoid arthritis.

ревматоидный артритдепрессиякогнитивные нарушенияприверженность терапииэффективность терапииrheumatoid arthritisdepressioncognitive impairmentstherapy adherenceefficiency of therapyReferencesNasonov EL, Karateev DE. Does Russia need a treat-to-target initiative? Rheumatology. 2015;54(3):381-2. doi:10.1093/rheumatology/keu156Nasonov EL, Karateev DE. Does Russia need a treat-to-target initiative? Rheumatology. 2015;54(3):381-2. doi:10.1093/rheumatology/keu156Sokka T, Kautiainen H, Pincus T, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study. Arthritis Res Ther. 2010;12(2):R42. doi: 10.1186/ar2951Sokka T, Kautiainen H, Pincus T, et al. Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA Study. Arthritis Res Ther. 2010;12(2):R42. doi: 10.1186/ar2951Gabriel S, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi: 10.1186/ar2669Gabriel S, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229. doi: 10.1186/ar2669Комиссинская ИГ, Степченко АА, Ворона ИС. Фармакоэкономические аспекты лечения ревматоидного артрита. Курский научно-практический вестник «Человек и его здоровье». 2008;(3):123-9 [Komissinskaya IG, Stepchenko AA, Vorona IS. Pharmacoeconomic aspects of treating rheumatoid arthritis. Kurskiy Nauchno-Prakticheskiy Vestnik "Chelovek I Ego Zdorov’e". 2008;(3):123-9 (In Russ.)].Комиссинская ИГ, Степченко АА, Ворона ИС. Фармакоэкономические аспекты лечения ревматоидного артрита. Курский научно-практический вестник «Человек и его здоровье». 2008;(3):123-9 [Komissinskaya IG, Stepchenko AA, Vorona IS. Pharmacoeconomic aspects of treating rheumatoid arthritis. Kurskiy Nauchno-Prakticheskiy Vestnik "Chelovek I Ego Zdorov’e". 2008;(3):123-9 (In Russ.)].Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62-8. doi: 10.1136/annrheumdis-2013-204223Dougados M, Soubrier M, Antunez A, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis. 2014;73(1):62-8. doi: 10.1136/annrheumdis-2013-204223Kekow J, Moots R, Khandker R, et al. Improvements in patient reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderateto-severe active early rheumatoid arthritis. Rheumatology. 2011;50:401-9. doi: 10.1093/rheumatology/keq327Kekow J, Moots R, Khandker R, et al. Improvements in patient reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderateto-severe active early rheumatoid arthritis. Rheumatology. 2011;50:401-9. doi: 10.1093/rheumatology/keq327Raftery G, He J, Pearce R, et al. Disease activity and cognition in rheumatoid arthritis: an open label pilot study. Arthritis Res Ther. 2012;14:R263. doi:10.1186/ar4108Raftery G, He J, Pearce R, et al. Disease activity and cognition in rheumatoid arthritis: an open label pilot study. Arthritis Res Ther. 2012;14:R263. doi:10.1186/ar4108Лисицына ТА, Вельтищев ДЮ, Краснов ВН, Насонов ЕЛ. Клинико-патогенетические взаимосвязи иммуновоспалительных ревматических заболеваний и психических расстройств. Клиническая медицина. 2014;(1):12-21 [Lisitsyna TA, Vel’tishchev DYu, Krasnov VN, Nasonov EL. Clinical and pathogenetic associations between immuno- inflammatory rheumatic diseases and mental disorders. Klinicheskaya Meditsina. 2014;(1):12-21 (In Russ.)].Лисицына ТА, Вельтищев ДЮ, Краснов ВН, Насонов ЕЛ. Клинико-патогенетические взаимосвязи иммуновоспалительных ревматических заболеваний и психических расстройств. Клиническая медицина. 2014;(1):12-21 [Lisitsyna TA, Vel’tishchev DYu, Krasnov VN, Nasonov EL. Clinical and pathogenetic associations between immuno- inflammatory rheumatic diseases and mental disorders. Klinicheskaya Meditsina. 2014;(1):12-21 (In Russ.)].Löwe B, Willand L, Fiehn Ch, et al. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. Psychosomatic Medicine. 2004;66(3):395-402.Löwe B, Willand L, Fiehn Ch, et al. Psychiatric comorbidity and work disability in patients with inflammatory rheumatic diseases. Psychosomatic Medicine. 2004;66(3):395-402.Joyce AT, Smith P, Khandker R, et al. Hidden cost of rheumatoid arthritis, estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol. 2009;36(4):743-52. doi: 10.3899/jrheum.080670Joyce AT, Smith P, Khandker R, et al. Hidden cost of rheumatoid arthritis, estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol. 2009;36(4):743-52. doi: 10.3899/jrheum.080670Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1013-9.Ang DC, Choi H, Kroenke K, Wolfe F. Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis. J Rheumatol. 2005;32:1013-9.Margaretten M, Julian L, Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheum. 2011;6(6):617-23. doi: 10.2217/IJR.11.6Margaretten M, Julian L, Katz P, Yelin E. Depression in patients with rheumatoid arthritis: description, causes and mechanisms. Int J Clin Rheum. 2011;6(6):617-23. doi: 10.2217/IJR.11.6Abbott R, Whear R, Nikolaou V, et al. Tumour necrosis factor-α inhibitor therapy in chronic physical illness: A systematic review and metaanalysis of the effect on depression and anxiety. J Psychosom Res. 2015 Sep;79(3):175-84. doi: 10.1016/j.jpsychores.2015.04.008Abbott R, Whear R, Nikolaou V, et al. Tumour necrosis factor-α inhibitor therapy in chronic physical illness: A systematic review and metaanalysis of the effect on depression and anxiety. J Psychosom Res. 2015 Sep;79(3):175-84. doi: 10.1016/j.jpsychores.2015.04.008Rathbun AM, Reed GW, Harrold LR. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology. 2013;52(10):1785-94. doi: 10.1093/rheumatology/kes356Rathbun AM, Reed GW, Harrold LR. The temporal relationship between depression and rheumatoid arthritis disease activity, treatment persistence and response: a systematic review. Rheumatology. 2013;52(10):1785-94. doi: 10.1093/rheumatology/kes356Sheehy C, Murphy E, Barry M. Depression in rheumatoid arthritis – underscoring the problem. Rheumatology. 2006;45(11):1325-7. doi: 10.1093/rheumatology/kel231Sheehy C, Murphy E, Barry M. Depression in rheumatoid arthritis – underscoring the problem. Rheumatology. 2006;45(11):1325-7. doi: 10.1093/rheumatology/kel231Couzin-Frankel J. Inflammation bares a dark side. Science. 2010;330(6011):1621-31. doi: 10.1126/science.330.6011.162Couzin-Frankel J. Inflammation bares a dark side. Science. 2010;330(6011):1621-31. doi: 10.1126/science.330.6011.162Strain JJ, Blumenfield M. Challenges for consultation-liaison psychiatry in the 21st Century. Psychosomatics. 2008;49:2. doi: 10.1176/appi.psy.49.2.93Strain JJ, Blumenfield M. Challenges for consultation-liaison psychiatry in the 21st Century. Psychosomatics. 2008;49:2. doi: 10.1176/appi.psy.49.2.93Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171-86. doi: 10.1097/PSY.0b013e3181907c1bHowren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171-86. doi: 10.1097/PSY.0b013e3181907c1bSchmidt FM, Lichtblau N, Minkwitz J, et al. Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. J Psychiatr Res. 2014;55:29-34. doi: 10.1016/j.jpsychires.2014.04.021Schmidt FM, Lichtblau N, Minkwitz J, et al. Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. J Psychiatr Res. 2014;55:29-34. doi: 10.1016/j.jpsychires.2014.04.021Gimeno D, Kivimaki M, Brunner EJ, et al. Associations of Creactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2009;39(3):413-23. doi: 10.1017/S0033291708003723Gimeno D, Kivimaki M, Brunner EJ, et al. Associations of Creactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med. 2009;39(3):413-23. doi: 10.1017/S0033291708003723Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31-41. doi: 10.1001/2013.jamapsychiatry.4Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31-41. doi: 10.1001/2013.jamapsychiatry.4Beratis S, Katrivanou A, Georgiou S, et al. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment. J Psychosom Res. 2005;58:15-8. doi: 10.1016/j.jpsychores.2004.03.010Beratis S, Katrivanou A, Georgiou S, et al. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment. J Psychosom Res. 2005;58:15-8. doi: 10.1016/j.jpsychores.2004.03.010Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-6. doi: 10.1056/NEJM200103293441303Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-6. doi: 10.1056/NEJM200103293441303Mattey DL, Dawes PT, Hassell AB, et al. Effect of psychological distress on continuation of anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. J Rheumatol. 2010;37(10):2021-4. doi: 10.3899/jrheum.100050Mattey DL, Dawes PT, Hassell AB, et al. Effect of psychological distress on continuation of anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. J Rheumatol. 2010;37(10):2021-4. doi: 10.3899/jrheum.100050Hider SL, Tanveer W, Brownfield A, et al. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. Rheumatology. 2009;48(9):1152-4. doi: 10.1093/rheumatology/kep170Hider SL, Tanveer W, Brownfield A, et al. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. Rheumatology. 2009;48(9):1152-4. doi: 10.1093/rheumatology/kep170Zautra AJ, Smith BW. Depression and reactivity to stress in older women with rheumatoid arthritis and osteoarthritis. Psychosom Med. 2001;63:687-96. doi: 10.1097/00006842-200107000-00022Zautra AJ, Smith BW. Depression and reactivity to stress in older women with rheumatoid arthritis and osteoarthritis. Psychosom Med. 2001;63:687-96. doi: 10.1097/00006842-200107000-00022Zautra AJ, Yocum DC, Villanueva I, et al. Immune activation and depression in women with rheumatoid arthritis. J Rheumatol. 2004;31:457-63.Zautra AJ, Yocum DC, Villanueva I, et al. Immune activation and depression in women with rheumatoid arthritis. J Rheumatol. 2004;31:457-63.Schieir O, Thombs BD, Hudson M, et al. Symptoms of depression predict the trajectory of pain among patients with early inflammatory arthritis: a path analysis approach to assessing change. J Rheumatol. 2009;36(2):231-9. doi: 10.3899/jrheum.080147Schieir O, Thombs BD, Hudson M, et al. Symptoms of depression predict the trajectory of pain among patients with early inflammatory arthritis: a path analysis approach to assessing change. J Rheumatol. 2009;36(2):231-9. doi: 10.3899/jrheum.080147Cabrera-Marroquin R, Contreras-Yanez I, Alcocer-Castillejos N, Pascual-Ramos V. Major depressive episodes are associated with poor concordance with therapy in rheumatoid arthritis patients: the impact on disease outcomes. Clin Exp Rheumatol. 2014;32(6):904-13.Cabrera-Marroquin R, Contreras-Yanez I, Alcocer-Castillejos N, Pascual-Ramos V. Major depressive episodes are associated with poor concordance with therapy in rheumatoid arthritis patients: the impact on disease outcomes. Clin Exp Rheumatol. 2014;32(6):904-13.Leblanc-Trudeau C, Dobkin PL, Carrier N, et al. Depressive symptoms predict future simple disease activity index scores and simple disease activity index remission in a prospective cohort of patients with early inflammatory polyarthritis. Rheumatology (Oxford). 2015;54(12):2205-14. doi: 10.1093/rheumatology/kev272Leblanc-Trudeau C, Dobkin PL, Carrier N, et al. Depressive symptoms predict future simple disease activity index scores and simple disease activity index remission in a prospective cohort of patients with early inflammatory polyarthritis. Rheumatology (Oxford). 2015;54(12):2205-14. doi: 10.1093/rheumatology/kev272Wong M, Mulherin D. The influence of medication beliefs and other psychosocial factors on early discontinuation of diseasemodifying anti-rheumatic drugs. Musculoskel Care. 2007;5(3):148-59. doi: 10.1002/msc.107Wong M, Mulherin D. The influence of medication beliefs and other psychosocial factors on early discontinuation of diseasemodifying anti-rheumatic drugs. Musculoskel Care. 2007;5(3):148-59. doi: 10.1002/msc.107Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. 720 с. [Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional’noe rukovodstvo [Rheumatology: National guidelines]. Moscow: GEOTAR-Media; 2008. 720 p. (In Russ.)].Насонов ЕЛ, Насонова ВА, редакторы. Ревматология: Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. 720 с. [Nasonov EL, Nasonova VA, editors. Revmatologiya: Natsional’noe rukovodstvo [Rheumatology: National guidelines]. Moscow: GEOTAR-Media; 2008. 720 p. (In Russ.)].Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67(10):1360-4. doi: 10.1136/ard.2008.091454Aletaha D, Landewe R, Karonitsch T, et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis. 2008;67(10):1360-4. doi: 10.1136/ard.2008.091454Kojioma M, Kojioma T, Suzuki S, et al. Depression, inflammation and pain in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(8):1018-24. doi: 10.1002/art.24647Kojioma M, Kojioma T, Suzuki S, et al. Depression, inflammation and pain in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(8):1018-24. doi: 10.1002/art.24647Ramsey-Goldman R, Rothrock N. Fatigue in systemic lupus erythematosus and rheumatoid arthritis. Amer Acad Phys Med Rehabil. 2010;2(5):384-92. doi: 10.1016/j.pmrj.2010.03.026Ramsey-Goldman R, Rothrock N. Fatigue in systemic lupus erythematosus and rheumatoid arthritis. Amer Acad Phys Med Rehabil. 2010;2(5):384-92. doi: 10.1016/j.pmrj.2010.03.026Inanc N, Yilmaz-Oner S, Can M, et al. The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis. J Rheumatol. 2014;41(9):1755-60. doi: 10.3899/jrheum.131171Inanc N, Yilmaz-Oner S, Can M, et al. The role of depression, anxiety, fatigue, and fibromyalgia on the evaluation of the remission status in patients with rheumatoid arthritis. J Rheumatol. 2014;41(9):1755-60. doi: 10.3899/jrheum.131171Ranzolin A, Tavares Brenol JC, Bredemeier M. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(6):794-800. DOI: 10.1002/art.24430Ranzolin A, Tavares Brenol JC, Bredemeier M. Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis Rheum. 2009;61(6):794-800. DOI: 10.1002/art.24430Boomershine ChS. Effective rheumatoid arthritis treatment requires comprehensive management strategies. Arthr Res Ther. 2009;11:138. doi: 10.1186/ar2872Boomershine ChS. Effective rheumatoid arthritis treatment requires comprehensive management strategies. Arthr Res Ther. 2009;11:138. doi: 10.1186/ar2872Cordingley L, Prajapati R, Plant D. The Biologics In Rheumatoid Arthritis Genetics And Genomics Study Syndicate (Braggss), Barton A. Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis. Arthr Care Res. 2014;66(6):861-8. doi: 10.1002/acr.22249Cordingley L, Prajapati R, Plant D. The Biologics In Rheumatoid Arthritis Genetics And Genomics Study Syndicate (Braggss), Barton A. Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis. Arthr Care Res. 2014;66(6):861-8. doi: 10.1002/acr.22249Roubille C, Richer V, Starnino T. Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. J Rheumatol. 2015;42(10):1767-80. doi: 10.3899/jrheum.141112Roubille C, Richer V, Starnino T. Evidence-based Recommendations for the Management of Comorbidities in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis: Expert Opinion of the Canadian Dermatology-Rheumatology Comorbidity Initiative. J Rheumatol. 2015;42(10):1767-80. doi: 10.3899/jrheum.141112Uguz F, Akman C, Kucuksarac S, Tufekci O. Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin Neurosci. 2009;63(1):50-5. doi: 10.1111/j.1440-1819.2008.01905.xUguz F, Akman C, Kucuksarac S, Tufekci O. Anti-tumor necrosis factor-alpha therapy is associated with less frequent mood and anxiety disorders in patients with rheumatoid arthritis. Psychiatry Clin Neurosci. 2009;63(1):50-5. doi: 10.1111/j.1440-1819.2008.01905.xHoving JL, Bartelds GM, Sluiter JK, et al. Perceived work ability, quality of life and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand J Rheumatol. 2009;38:246-50. doi: 10.1080/03009740902748264Hoving JL, Bartelds GM, Sluiter JK, et al. Perceived work ability, quality of life and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand J Rheumatol. 2009;38:246-50. doi: 10.1080/03009740902748264Moreland LW, Genovese MC, Sato R, Singh A. Effect of Etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthr Care Res. 2006;55(2):287-93. doi: 10.1002/art.21838Moreland LW, Genovese MC, Sato R, Singh A. Effect of Etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthr Care Res. 2006;55(2):287-93. doi: 10.1002/art.21838Wolf F, Michaud K. Fatigue, rheumatoid arthritis and anti-tumor necrosis factor therapy: an investigation in 24831 patients. J Rheumatol. 2004;31(11):2115-20.Wolf F, Michaud K. Fatigue, rheumatoid arthritis and anti-tumor necrosis factor therapy: an investigation in 24831 patients. J Rheumatol. 2004;31(11):2115-20.Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford). 2012;51(1):60-8. doi: 10.1093/rheumatology/ker162Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford). 2012;51(1):60-8. doi: 10.1093/rheumatology/ker162Van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology. 2010;49(7):1294-302. doi: 10.1093/rheumatology/keq043Van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology. 2010;49(7):1294-302. doi: 10.1093/rheumatology/keq043Taylor-Gjevre RM, Gjevre JA, Nair BV, et al. Improved sleep efficiency after anti-tumor necrosis factor a therapy in rheumatoid arthritis patients. Ther Adv Musculoskel Dis. 2011;3(5):227-33. doi: 10.1177/1759720X11416862Taylor-Gjevre RM, Gjevre JA, Nair BV, et al. Improved sleep efficiency after anti-tumor necrosis factor a therapy in rheumatoid arthritis patients. Ther Adv Musculoskel Dis. 2011;3(5):227-33. doi: 10.1177/1759720X11416862Лисицына ТА, Зелтынь АЕ, Вельтищев ДЮ и др. Расстройства тревожно-депрессивного спектра и когнитивные нарушения у больных ревматоидным артритом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;11(2):96-103 [Lisitsyna TA, Zeltyn’ AE, Vel’tishchev DYu, et al. Anxiety disorders and depressive disorders in rheumatoid arthritis patients. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;11(2):96-103 (In Russ.)].Лисицына ТА, Зелтынь АЕ, Вельтищев ДЮ и др. Расстройства тревожно-депрессивного спектра и когнитивные нарушения у больных ревматоидным артритом. Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;11(2):96-103 [Lisitsyna TA, Zeltyn’ AE, Vel’tishchev DYu, et al. Anxiety disorders and depressive disorders in rheumatoid arthritis patients. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2012;11(2):96-103 (In Russ.)].Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1200-5. doi: 10.1136/jnnp.74.9.1200Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1200-5. doi: 10.1136/jnnp.74.9.1200Лисицына ТА, Вельтищев ДЮ, Серавина ОФ и др. Провоспалительные цитокины и депрессия при ревматоидном артрите. Научно-практическая ревматология. 2013;51(3):261-6 [Lisitsyna TA, Vel'tishchev DYu, Seravina OF, et al. Anti-inflammatory cytokines and depression in rheumatoid arthritis patients. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):261-6 (In Russ.)]. doi: 10.14412/1995-4484-2013-1498Лисицына ТА, Вельтищев ДЮ, Серавина ОФ и др. Провоспалительные цитокины и депрессия при ревматоидном артрите. Научно-практическая ревматология. 2013;51(3):261-6 [Lisitsyna TA, Vel'tishchev DYu, Seravina OF, et al. Anti-inflammatory cytokines and depression in rheumatoid arthritis patients. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(3):261-6 (In Russ.)]. doi: 10.14412/1995-4484-2013-1498Mü ller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des. 2008;14(14):1452-65. doi: 10.2174/138161208784480243Mü ller N, Schwarz MJ. COX-2 inhibition in schizophrenia and major depression. Curr Pharm Des. 2008;14(14):1452-65. doi: 10.2174/138161208784480243Hayden KM, Zandi PP, Khachaturian AS, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache Country study. Neurology. 2007;69(3):275-82. doi: 10.1212/01.wnl.0000265223.25679.2aHayden KM, Zandi PP, Khachaturian AS, et al. Does NSAID use modify cognitive trajectories in the elderly? The Cache Country study. Neurology. 2007;69(3):275-82. doi: 10.1212/01.wnl.0000265223.25679.2aTobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammat. 2008;5(1):2. doi: 10.1186/1742-2094-5-2Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammat. 2008;5(1):2. doi: 10.1186/1742-2094-5-2Janssen DGA, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol Clin Exp. 2010;25(3):201-15. doi: 10.1002/hup.1103Janssen DGA, Caniato RN, Verster JC, Baune BT. A psychoneuroimmunological review on cytokines involved in antidepressant treatment response. Hum Psychopharmacol Clin Exp. 2010;25(3):201-15. doi: 10.1002/hup.1103Slaughter JR, Parker JC, Martens MP, et al. Clinical outcomes following a trial of sertraline in rheumatoid arthritis. Psychosom. 2002;43(1):36-41. doi: 10.1176/appi.psy.43.1.36Slaughter JR, Parker JC, Martens MP, et al. Clinical outcomes following a trial of sertraline in rheumatoid arthritis. Psychosom. 2002;43(1):36-41. doi: 10.1176/appi.psy.43.1.36Richards BL, Whittle SL, van der Heijde DM, Buchbinder R. The efficacy and safety of antidepressants in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012 Sep;90:21-7. doi: 10.3899/jrheum.120338Richards BL, Whittle SL, van der Heijde DM, Buchbinder R. The efficacy and safety of antidepressants in inflammatory arthritis: a Cochrane systematic review. J Rheumatol Suppl. 2012 Sep;90:21-7. doi: 10.3899/jrheum.120338Miller AH, Maletic V, Raison ChL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732-41. doi: 10.1016/j.biopsych.2008.11.029Miller AH, Maletic V, Raison ChL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732-41. doi: 10.1016/j.biopsych.2008.11.029Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun. 2002;16(5):569-74. doi: 10.1016/S0889-1591(02)00008-9Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun. 2002;16(5):569-74. doi: 10.1016/S0889-1591(02)00008-9Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatr. 2010;15(5):473-500. doi: 10.1038/mp.2008.116Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatr. 2010;15(5):473-500. doi: 10.1038/mp.2008.116Bian-Sheng JI, He JI, Guo-Ging LIU. Doxepine protects cultured neurons against oxidative stress-induced injury. Acta Pharmacol Sin. 2004;25(3):297-300.Bian-Sheng JI, He JI, Guo-Ging LIU. Doxepine protects cultured neurons against oxidative stress-induced injury. Acta Pharmacol Sin. 2004;25(3):297-300.Ash G, Dickens CM, Creed FH, et al. The effects of dothiepin on subjects with rheumatoid arthritis and depression. Rheumatology. 1999;38:959-67. doi: 10.1093/rheumatology/38.10.959Ash G, Dickens CM, Creed FH, et al. The effects of dothiepin on subjects with rheumatoid arthritis and depression. Rheumatology. 1999;38:959-67. doi: 10.1093/rheumatology/38.10.959Huber AM, Tomlinson GA, Koren G, Feldman BM. Amitriptyline to relieve pain in Juvenile Idiopathic Arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 Clinical Trials. J Rheumatol. 2007;34:1125-32. doi: 10.1186/ISRCTN95255919Huber AM, Tomlinson GA, Koren G, Feldman BM. Amitriptyline to relieve pain in Juvenile Idiopathic Arthritis: a pilot study using Bayesian metaanalysis of multiple N-of-1 Clinical Trials. J Rheumatol. 2007;34:1125-32. doi: 10.1186/ISRCTN95255919Fishbain DA, Cutler RB, Lewis J, et al. Do second-generation «atypical neuroleptics» have analgesic properties: a structured evidence-based review. Pain Med. 2004;5(4):359-65. doi: 10.1111/j.1526-4637.2004.04054.xFishbain DA, Cutler RB, Lewis J, et al. Do second-generation «atypical neuroleptics» have analgesic properties: a structured evidence-based review. Pain Med. 2004;5(4):359-65. doi: 10.1111/j.1526-4637.2004.04054.x

The authors declare that there are no conflicts of interest present.